

Changing the game of iCTX: inhaled cannabis therapeutics

Perlen Packaging and Merxin Ltd announce exclusive worldwide agreement to develop inhaled cannabis therapies.

Merxin Ltd (UK) and Perlen Packaging (CH) have signed an exclusive worldwide agreement to bring Perlen's BLISTair DPI inhaler device to the cannabis market through Merxin's expertise in inhaled drug delivery. Merxin will develop and market BLISTair cannabis dosage forms in collaboration with Perlen.

Philippe Rogueda (Merxin Ltd): "Inhaled cannabinoid therapies are a growing segment at Merxin, it is a very exciting market with a lot to invent. The BLISTair is one of the most elegant DPI devices on the market, recipient of multiple awards over the last year. I am thrilled to have secured an agreement with Perlen to create formulations for the BLISTair and bring much needed dosed, safe and reliable cannabis therapies to a market waiting for them.

Perlen is a natural fit for us: creative, determined and focussed; we are the future."

Matteo Trisoglio (Business Development Manager, Perlen Packaging): "The BLISTair was developed with the intention to be the most attractable and innovative disposable inhaler. Current requests are proving that our intention and the set targets with this device can become real. Offering, further, the complete CMO solution is a supplementary and unique USP of the complete business model. With Merxin on our site, dedicated to the CBD-Market, we can and will create supplementary values, improve the quality of life of patients Worldwide. The suitable indications for CBD and the easiness of inhalation, on a disposable, low cost device is the perfect match."

Cannabis Therapeutics or CTX. The market for CTX is only just forming and is currently valued at USD 31.4 Billion, set to grow to USD 145 Billion by 2025. The market is eager for dosed, safe and reproducible therapies. The inhaled route is ideal for this application. Cannabinoids have been used therapeutically for millennia throughout the world; contemporary inhaled Cannabinoid Therapeutics (iCTX) will carry this tradition into the future in safe and efficient forms.

The PERLAMED™-BLISTair is a single use inhaler on a thermoformed blister basis, completely manufactured on one blister machine, incorporating primary and secondary packaging in one device. The BLISTair device is together an air intake, mouth piece, powder enclosure, dispensing system aerosolisation engine.

Merxin has been active in the field of cannabis therapeutics for a while. MRX002, its pMDI formulation tool, is very popular with cannabinoid pMDI formulators in the US. Merxin is also very active with research groups developing devices for inhaled cannabis therapies based on its MRX001 and MRX003 technologies. Merxin was certified ISO 13485:2016 for the design and supply of inhaler devices including cannabinoid inhalers.



About Perlen (www.perlenpackaging.com): Perlen Packaging is an internationally active group of companies in the field of film manufacturing and film coating. Perlen is the only systems provider of packaging films with a clearly defined pharmaceutical profile. Processes, facilities, products and environment are geared to the needs of the pharmaceutical industry.

About Merxin (www.merxin.com): Merxin is a medical device designer and supplier that provides its clients with a lower cost and lower risk route to market. Merxin is famous for its bio-equivalent generic inhalers of Diskus, HandiHaler and Respimat. The Merxin team has a thorough understanding and long history of medical device and pharmaceutical product development: www.merxin.com. #Reduce Cost, #Reduce Risk, #Increase Success.

Contacts

For Merxin: Dr Philippe Rogueda, philippe@merxin.com

For Perlen: Mr Matteo Trisoglio, Matteo.Trisoglio@perlenpackaging.com

Date: 25 February 2019



Perlen Packaging
Perlen, Switzerland

